Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will be discussing 3Q20 financial results with the investment community.on 16th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.sunesis.com
Investors who wish to participate in the conference call may call, (844) 296-7720 Toll Free, (United States) or (574) 990-1148 Toll Number, when prompted, enter passcode 1776248
Earnings Expectation
Sunesis Pharmaceuticals, Inc. is expected to report third quarter earnings results, after market close, on Monday 16th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.34 per share from revenue of $ 0.00 million. Looking ahead, the full year loss are expected at $ 1.62 per share on the revenues of $ 0.11 million.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Brutons tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia.
